Francesco Nuzzo

3.2k total citations · 1 hit paper
48 papers, 1.2k citations indexed

About

Francesco Nuzzo is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Francesco Nuzzo has authored 48 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 19 papers in Cancer Research and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Francesco Nuzzo's work include Cancer Treatment and Pharmacology (21 papers), Breast Cancer Treatment Studies (18 papers) and Advanced Breast Cancer Therapies (10 papers). Francesco Nuzzo is often cited by papers focused on Cancer Treatment and Pharmacology (21 papers), Breast Cancer Treatment Studies (18 papers) and Advanced Breast Cancer Therapies (10 papers). Francesco Nuzzo collaborates with scholars based in Italy, Malaysia and France. Francesco Nuzzo's co-authors include A. De Matteis, Francesco Perrone, Ciro Gallo, Michelino De Laurentiis, Maria Carmela Piccirillo, Massimo Di Maïo, Alessandro Morabito, Fortunato Ciardiello, Cesare Gridelli and Gennaro Daniele and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Francesco Nuzzo

46 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

2015 330 citations Massimo Di Maïo, Ciro Gallo et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Francesco Nuzzo Italy	15	710	355	351	229	150	48	1.2k
Vernon Harvey New Zealand	22	1.3k 1.8×	357 1.0×	489 1.4×	258 1.1×	67 0.4×	44	1.8k
Cynthia Osborne United States	9	1.0k 1.4×	282 0.8×	432 1.2×	441 1.9×	91 0.6×	12	1.5k
Musa Mayer United States	17	1.3k 1.8×	760 2.1×	562 1.6×	328 1.4×	97 0.6×	55	1.9k
Ray Snyder Australia	10	652 0.9×	170 0.5×	251 0.7×	144 0.6×	93 0.6×	14	843
Christian R. Loehberg Germany	22	539 0.8×	362 1.0×	677 1.9×	375 1.6×	63 0.4×	59	1.5k
Phuong K. Morrow United States	24	1.0k 1.5×	396 1.1×	283 0.8×	525 2.3×	56 0.4×	65	1.8k
Mauro Mansutti Italy	16	1.1k 1.5×	331 0.9×	713 2.0×	187 0.8×	66 0.4×	43	1.5k
Álvaro Rodríguez-Lescure Spain	17	714 1.0×	230 0.6×	503 1.4×	217 0.9×	51 0.3×	71	1.1k
P. Hupperets Netherlands	21	629 0.9×	266 0.7×	340 1.0×	328 1.4×	46 0.3×	40	1.4k
Lissandra Dal Lago Belgium	18	1.2k 1.6×	254 0.7×	219 0.6×	305 1.3×	81 0.5×	54	1.7k

Countries citing papers authored by Francesco Nuzzo

Since Specialization

Citations

This map shows the geographic impact of Francesco Nuzzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesco Nuzzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesco Nuzzo more than expected).

Fields of papers citing papers by Francesco Nuzzo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesco Nuzzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesco Nuzzo. The network helps show where Francesco Nuzzo may publish in the future.

Co-authorship network of co-authors of Francesco Nuzzo

This figure shows the co-authorship network connecting the top 25 collaborators of Francesco Nuzzo. A scholar is included among the top collaborators of Francesco Nuzzo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesco Nuzzo. Francesco Nuzzo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Buono, Giuseppe, Monica Capozzi, Roberta Caputo, et al.. (2024). CAR-T cell therapy for breast cancer: Current status and future perspective. Cancer Treatment Reviews. 133. 102868–102868. 7 indexed citations

Arenare, Laura, Raimondo Di Liello, Pietro De Placido, et al.. (2024). Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials. ESMO Open. 9(3). 102941–102941. 3 indexed citations

Caputo, Roberta, Giuseppe Buono, Michela Piezzo, et al.. (2024). Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis. Frontiers in Oncology. 14. 1362641–1362641. 29 indexed citations

Pacilio, Carmen, Gerardo Rosati, Anna Crispo, et al.. (2023). An Overview of the Roles of CDK4/6 Inhibitors in Metastatic Breast Cancer Elderly Patients. In Vivo. 37(4). 1445–1449. 5 indexed citations

Munzone, Elisabetta, Alessandra Fabi, Giuseppe Buono, et al.. (2023). The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+ Breast Cancer Patients. Drugs & Therapy Perspectives. 39(12). 432–446.

Buono, Giuseppe, Grazia Arpino, Lucia Del Mastro, et al.. (2022). Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice. Frontiers in Oncology. 12. 1032166–1032166. 4 indexed citations

Piezzo, Michela, Stefania Cocco, Roberta Caputo, et al.. (2020). Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors. International Journal of Molecular Sciences. 21(18). 6479–6479. 126 indexed citations

Yardley, Denise A., Sara A. Hurvitz, Masakazu Toi, et al.. (2017). Abstract P4-22-13: Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-1. Cancer Research. 77(4_Supplement). P4–22. 3 indexed citations

Perrone, Francesco, Claudio Jommi, Massimo Di Maïo, et al.. (2016). The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy. Annals of Oncology. 27(12). 2224–2229. 108 indexed citations

10.

Maïo, Massimo Di, Ciro Gallo, Natasha B. Leighl, et al.. (2015). Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials. Journal of Clinical Oncology. 33(8). 910–915. 330 indexed citations breakdown →

11.

Perrone, Francesco, Francesco Nuzzo, Francesca Di Rella, et al.. (2014). Weekly Docetaxel (Wd) Vs Cmf As Adjuvant Chemotherapy for Elderly Early Breast Cancer (Ebc) Patients (Pts): Final Results from the Randomised Phase 3 Elda Trial. Annals of Oncology. 25. iv86–iv86. 1 indexed citations

12.

Nuzzo, Francesco, Alessandro Morabito, Ermelinda De Maio, et al.. (2007). Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: Safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology. 66(2). 171–180. 20 indexed citations

13.

Morabito, Alessandro, Maria Carmela Piccirillo, Carmen Pacilio, et al.. (2007). First-Line Chemotherapy for HER-2–Negative Metastatic Breast Cancer Patients Who Received Anthracyclines as Adjuvant Treatment. The Oncologist. 12(11). 1288–1298. 5 indexed citations

14.

Pacilio, Carmen, Alessandro Morabito, Francesco Nuzzo, et al.. (2006). Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. British Journal of Cancer. 94(9). 1233–1236. 21 indexed citations

15.

Matteis, A. De, Francesco Nuzzo, Giuseppe D’Aiuto, et al.. (2002). Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast. Cancer. 94(4). 895–901. 10 indexed citations

16.

Tampellini, Marco, Alfredo Berruti, G. Gorzegno, et al.. (2001). Independent Factors Predict Supranormal CA 15-3 Serum Levels in Advanced Breast Cancer Patients at First Disease Relapse. Tumor Biology. 22(6). 367–373. 14 indexed citations

17.

Placido, Sabino De, Francesco Nuzzo, Francesco Perrone, et al.. (1995). The First Breast Cancer Screening Program in Southern Italy: Preliminary Results from Three Municipalities of the Naples Province. Tumori Journal. 81(1). 7–12. 8 indexed citations

18.

Palmieri, Giuseppe, Rossella Lauria, Francesco Caponigro, et al.. (1990). Salvage chemotherapy for non Hodgkin's lymphoma of unfavourable histology with a combination of ccnu and vinblastine. Hematological Oncology. 8(4). 179–183. 6 indexed citations

19.

Nuzzo, Francesco & Mario Stefanini. (1989). Monitoring of genetic instability in subjects with increased risk of cancer.. PubMed. 25(1). 81–9. 1 indexed citations

20.

Marin, G., Francesco Nuzzo, & L. De Carli. (1960). Analisi di alcuni fattori sperimentali che influenzano le curve di sopravvivenza ai raggi X di cellule umane coltivate in vitro. Il Nuovo Cimento. 18(S2). 227–236. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact